Ribavirin and interferon-α combination therapy vs interferon-α alone in the retreatment of chronic hepatitis C: A randomized clinical trial

Journal of Viral Hepatitis

Volumn 4, Issue 3, 1997, Pages 185-192

  Bellobuono, A ^a   Mondazzi, L ^a   Tempini, S ^a   Silini, E ^b   Vicari, F ^a   Ideo G ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Chronic hepatitis C; Combination therapy; Hepatitis C virus; Interferon ; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0031136448     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1997.00142.x     Document Type: Article

References (26)

1. Bellentani S, Tiribelli C, Saccoccio G et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos study. Hepatology 1994; 20: 1442-1449.
2. Alter MJ, Shapiro CN, Coleman PJ, Margolis HS. Viral hepatitis in North America. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Proceedings of the International Symposium on Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag 1994: 439-443.
3. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1509-1511.
4. Tinè F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991; 13: 192-199.
5. Shindo M, Di Bisceglie AM, Cheung L et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-704.
6. Reichard O, Glaumann H, Norkrans G et al. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver 1994; 14: 169-174.
7. Saracco G, Rosina F, Abate ML et al. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon alfa-2b. Hepatology 1993; 18: 1300-1305.
8. Garson JA, Brillanti S, Ring C, Perini P, Miglioli M, Barbara L. Hepatitis C viremia rebound after 'successful' interferon therapy in patients with chronic non-A, non-B hepatitis. J Med Virol 1992; 37: 210-214.
9. Chemello L, Bonetti P, Cavalletto L et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
10. Kasahara A, Hayashi N, Hiramatsu N et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291-297.
11. Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291.
12. Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B. High-dose interferon-α2b for retreatment of non-responders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Dig Dis Sci 1996; 41: 149-154.
13. Marcellin P, Boyer N, Pouteau M, Benhamou P, Erlinger S. Retreatment with interferon-α of chronic hepatitis C virus infection. Lancet 1994; 344: 690-691.
14. Cimino L, Citarella C, Nardone G, Budillon G. Lymphoblastoid interferon in chronic hepatitis C patients, non-responders to recombinant interferon-α (rIFN-α). J Hepatol 1992; 2-3: 419-420.
15. Hidenori T, Nakano S, Takeda I et al. Retreatment of chronic hepatitis C with interferon. Am J Gastroenterol 1994; 89: 1453-1457.
16. Sidwell RW, Robins RK, Hillyard IW. Ribavirin: an antiviral agent. Pharmacol Ther 1979; 6: 123-146.
17. Dusheiko G, Weiland O, Thomas H et al. Results of a placebo-controlled study of ribavirin in patients with chronic hepatitis C. Hepatology 1994; 20 (4): 206A.
18. Di Bisceglie AM, Conjeevaram HS, Fried MW et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.
19. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23 (suppl 2): 13-16.
20. Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23 (suppl 2): 17-21.
21. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-679.
22. Okamoto H, Tokita H, Sakamoto M et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74: 2385-2390.
23. Simmonds P, Holmes EC, Cha TA et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-2399.
24. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
25. Silini E, Bono F, Cividini A et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285-290.
26. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 (suppl 2): 8-12.